Prelude Therapeutics' SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

• Encouraging signs of anti-tumor activity including objective responses observed in patients with SMARCA4- mutated non-small cell lung cancer (NSCLC) and esophageal cancer in early PRT3789 monotherapy dose escalation - At doses studied to date, PRT3789 was generally well-tolerated with no dose-limiting toxicities or study drugrelated serious adverse events - Company to host investor conference call and webcast on Friday, September 13, 2024 at 12:00 PM EST WILMINGTON, Del., Sept. 13, 2024 (GLOBE NEWSWIRE) - ...